- Primary: To determine whether cotrimoxazole offers a survival benefit for HIV-exposed uninfected children
- Secondary: To evaluate the effect of breastfeeding duration on child mortality
Study Design: Double-blind, randomized, placebo-controlled trial
Study Population: Women living with HIV, age ≥18 years, >26 weeks gestation and < 34 days postpartum, and their infants
Study Duration: 4 years
Sponsor: National Institutes of Health (NIH)
Prophylactic co-trimoxazole seems to offer no survival benefit among HEU children in non-malarial, low-breastfeeding areas with a low risk of mother-to-child transmission of HIV.